⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529491 | 0.77 | — | — | |
| SCHEMBL1127169 | 0.74 | — | — | |
| SCHEMBL8354695 | 0.74 | — | — | |
| SCHEMBL1478909 | 0.71 | — | — | |
| SCHEMBL1479134 | 0.71 | — | — | |
| SCHEMBL7956854 | 0.71 | — | — | |
| SCHEMBL9386 | 0.71 | — | — | |
| SCHEMBL1479715 | 0.69 | MGLL (0.52) | — | |
| SCHEMBL529202 | 0.69 | — | — | |
| SCHEMBL23794036 | 0.69 | KAT2B (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678462-B | Isoindolinone inhibitors of MDM2-P53 interaction and methods of making the same | 阿斯泰克斯治疗有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-11603367-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | ASTEX THERAPEUTICS LIMITED (GB) | 2023-03-14 | — | — | US | disclosed |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| EP-3601272-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | Astex Therapeutics Limited (GB) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178691-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | WO | disclosed |
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1697355-A2 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-7101880-B2 | Peptidic compounds as cysteine protease inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| WO-2005063742-A2 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| WO-2004000838-A1 | PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |